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Background-—The usefulness of vascular function tests for management of patients with a history of coronary artery disease is not
fully known.
Methods and Results-—We measured ﬂow-mediated vasodilation (FMD) and brachial–ankle pulse wave velocity (baPWV) in 462
patients with coronary artery disease for assessment of the predictive value of FMD and baPWV for future cardiovascular events in
a prospective multicenter observational study. The ﬁrst primary outcome was coronary events, and the second primary outcome
was a composite of coronary events, stroke, heart failure, and sudden death. During a median follow-up period of 49.2 months, the
ﬁrst primary outcome occurred in 56 patients and the second primary outcome occurred in 66 patients. FMD above the cutoff
value of 7.1%, derived from receiver-operator curve analyses for the ﬁrst and second primary outcomes, was signiﬁcantly
associated with lower risk of the ﬁrst (hazard ratio, 0.27; 95% conﬁdence interval, 0.06–0.74; P=0.008) and second (hazard ratio,
0.32; 95% conﬁdence interval, 0.09–0.79; P=0.01) primary outcomes. baPWV above the cutoff value of 1731 cm/s was
signiﬁcantly associated with higher risk of the ﬁrst (hazard ratio, 1.86; 95% conﬁdence interval, 1.01–3.44; P=0.04) and second
(hazard ratio, 2.19; 95% conﬁdence interval, 1.23–3.90; P=0.008) primary outcomes. Among 4 groups stratiﬁed according to the
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combination of cutoff values of FMD and baPWV, stepwise increases in the calculated risk ratio for the ﬁrst and second primary
outcomes were observed.
Conclusions-—In patients with coronary artery disease, both FMD and baPWV were signiﬁcant predictors of cardiovascular events.
The combination of FMD and baPWV provided further cardiovascular risk stratiﬁcation.
Clinical Trial Registration-—URL: www.umin.ac.jp. Unique identiﬁer: UMIN000012950. ( J Am Heart Assoc. 2018;7:e008588.
DOI: 10.1161/JAHA.118.008588.)
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P atients with a history of coronary artery disease (CAD)are at high risk for subsequent cardiovascular events and
need intensive risk-reduction therapies to prevent recurrent
cardiovascular events.1–4 However, despite recent advances
in the understanding and management of CAD, some
optimally treated patients with CAD still have recurrent
cardiovascular events.5,6 Since the number of evidence-based
therapies that reduce cardiovascular morbidity and mortality
in high-risk patients receiving standard therapy has been
increasing, identiﬁcation of individuals at especially high risk
of recurrent cardiovascular events is necessary to select
candidates for individualized intensive risk-reduction thera-
pies in patients with established CAD for secondary preven-
tion. However, risk stratiﬁcation strategies in patients with
CAD are not well established.
Noninvasive vascular function tests have been developed
and performed for assessment of functional vascular damage
and severity of atherosclerosis.7–9 Impairment of vascular
function, such as endothelial dysfunction and increased
arterial stiffness, is closely associated with the development
and maintenance of atherosclerotic conditions, leading to
target organ damage and cardiovascular complications.10
Therefore, vascular function tests could be used not only as
markers of atherosclerosis but also as prognostic markers of
cardiovascular events.11 Recent meta-analyses have shown
that ﬂow-mediated vasodilation (FMD), an index of endothelial
function, and brachial–ankle pulse wave velocity (baPWV), an
index of arterial stiffness, are signiﬁcant predictors of
cardiovascular events independent of conventional cardiovas-
cular risk factors.12–16 However, there have only been a few
studies in which the predictive values of FMD, baPWV, and a
combination of FMD and baPWV in patients with established
CAD were investigated. Therefore, unfortunately, the useful-
ness of FMD and baPWV for risk stratiﬁcation of patients with
CAD has not been fully investigated. FMD-J (Flow-Mediated
Dilation Japan) Study A was a prospective multicenter
observational study designed to assess the predictive value
of FMD for future cardiovascular events in patients with CAD
independent of conventional cardiovascular risk factors and to
evaluate the usefulness of a multimarker strategy to assess
the prognosis of patients with CAD.17 The purpose of this
multicenter study was to determine whether FMD, baPWV,
and a combination of FMD and baPWV could be used as
independent markers to predict the risk of recurrent cardio-
vascular events in patients with established CAD.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for the purpose of
reproducing the results or replicating the procedure.
Study Design
The rationale and design of FMD-J Study A have been
described previously.17 This study was a prospective multi-
center observational cohort study conducted at 22 university
hospitals and afﬁliated clinics in Japan to examine the
usefulness of FMD assessment for the management of
Japanese patients with CAD with a 3-year follow-up period.17
Clinical Perspective
What Is New?
• Flow-mediated vasodilation above the cutoff value of 7.1%
was signiﬁcantly associated with lower risk of cardiovascu-
lar events in patients with a history of coronary artery
disease (CAD).
• Brachial-ankle pulse wave velocity above the cutoff value of
1731 cm/s was signiﬁcantly associated with higher risk of
cardiovascular events in patients with CAD.
• The combination of ﬂow-mediated vasodilation and
brachial–ankle pulse wave velocity provided further risk
stratiﬁcation of patients with CAD.
What Are the Clinical Implications?
• Measurements of both ﬂow-mediated vasodilation and
brachial–ankle pulse wave velocity are recommended for
cardiovascular risk assessment in patients with CAD.
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The ethical committees of the participating institutions
approved the study protocol. The study was executed in
accordance with the Good Clinical Practice guidelines.
Informed consent for participation in the study was obtained
from all subjects. The protocol was registered in the
University Hospital Medical Information Network Clinical
Trials Registry (UMIN000012950).
Study Patients
Patients aged 20 to 74 years who had a diagnosis of CAD and
who had been under regular follow-up at any of the
participating institutions for at least 6 months were eligible
for enrollment in FMD-J Study A. CAD was deﬁned as
myocardial infarction, angina pectoris with organic stenosis of
at least 1 coronary artery conﬁrmed by diagnostic imaging (ie,
coronary angiography, cardiac nuclear scintigraphy, or coro-
nary computed tomography), or previous percutaneous coro-
nary intervention. The exclusion criteria were as follows: a
history of coronary bypass surgery; severe valvular heart
disease; arrhythmia that requires treatment (ie, atrial ﬁbrilla-
tion, atrial ﬂutter, permanent pacemaker implantation or
frequent ventricular premature beats); severe chronic heart
failure (New York Heart Association level of >Level III);
malignancy; undergoing treatment with steroids, nonsteroidal
anti-inﬂammatory drugs, or immunosuppressive drugs; a
serum creatinine level >2.5 mg/dL; a history of stroke, aortic
disease (except peripheral artery disease), or serious liver
disease; and judgment of an attending physician that an
individual is ineligible for inclusion in the study.
Study Procedures
FMD and PWV measurements and blood examinations were
conducted at the start of the study. Cardiovascular events
were monitored annually during the 3-year follow-up period.
The participants were managed by their attending physicians,
who were encouraged to treat cardiovascular risk factors,
including hypertension, dyslipidemia, and diabetes mellitus, to
achieve the best of available standard of care in accordance
with guidelines.
Measurements of FMD and baPWV and
Assessment of Cardiovascular Risk Factors
Subjects fasted the previous night and abstained from
consuming alcohol, smoking, consuming caffeine, and taking
antioxidant vitamins on the day of the examination. Each
subject was kept in the supine position in a quiet, dark, and
air-conditioned room (constant temperature of 23–26°C)
throughout the study. A 23-gauge polyethylene catheter was
inserted into the left deep antecubital vein to obtain blood
samples. FMD and baPWV were measured at least 20 min-
utes after maintaining the supine position. The observers were
blind to the form of examination.
Vascular response to reactive hyperemia in the brachial
artery was used for assessment of endothelium-dependent
FMD. A high-resolution linear artery transducer was coupled
to computer-assisted analysis software (UNEXEF18G, UNEX
Co, Nagoya, Japan) that used an automated edge detection
system for measurement of brachial artery diameter. A blood
pressure cuff was placed around the forearm. The brachial
artery was scanned longitudinally 5 to 10 cm above the
elbow. When the clearest B-mode image of the anterior and
posterior intimal interfaces between the lumen and vessel
wall was obtained, the transducer was held at the same point
throughout the scan by a special probe holder (UNEX Co) to
ensure consistency of the image. Depth and gain setting were
set to optimize the images of the arterial lumen wall interface.
When the tracking gate was placed on the intima, the artery
diameter was automatically tracked, and the waveform of
diameter changes over the cardiac cycle was displayed in real
time using the FMD mode of the tracking system. This allowed
the ultrasound images to be optimized at the start of the scan
and the transducer position to be adjusted immediately for
optimal tracking performance throughout the scan. Pulsed
Doppler ﬂow was assessed at baseline and during peak
hyperemic ﬂow, which was conﬁrmed to occur within 15 s
after cuff deﬂation. Blood ﬂow velocity was calculated from
the color Doppler data and was displayed as a waveform in
real time. The baseline longitudinal image of the artery was
acquired for 30 s, and then the blood pressure cuff was
inﬂated to 50 mm Hg above systolic pressure for 5 minutes.
The longitudinal image of the artery was recorded continu-
ously until 5 minutes after cuff deﬂation. Pulsed Doppler
velocity signals were obtained for 20 s at baseline and for
10 s immediately after cuff deﬂation. Changes in brachial
artery diameter were immediately expressed as percentage
change relative to the vessel diameter before cuff inﬂation.
FMD was automatically calculated as the percentage change
in peak vessel diameter from the baseline value. Percentage
of FMD [(Peak diameterBaseline diameter)/Baseline diam-
eter] was used for analysis. Blood ﬂow volume was calculated
by multiplying the Doppler ﬂow velocity (corrected for the
angle) by heart rate and vessel cross-sectional area (r2).
Reactive hyperemia was calculated as the maximum percent-
age increase in ﬂow after cuff deﬂation compared with
baseline ﬂow. All of the sonographers specialized in FMD
measurement at the participating institutions received train-
ing for a standard protocol of FMD measurement and training
for scanning and analysis of the record at the core laboratory
located in Tokyo Medical University. All recordings of brachial
artery scans obtained during the measurement of FMD were
sent from the participant institutions to the core laboratory in
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Tokyo Medical University by universal serial bus ﬂash drives
and were individually analyzed by a well-experienced reader at
the core laboratory without any information about the
patients. The intraclass correlation coefﬁcient between each
participating institutions and the core laboratory has been
previously described.18 The correlation coefﬁcient between
FMD analyzed at the core laboratory and participant institu-
tions was 0.84 (P<0.001).
baPWV was measured using a volume-plethysmographic
apparatus (Form PWV/ABI, Omron Health Care Co, Kyoto,
Japan). Four oscillometric cuffs were wrapped around both
upper arms and lower legs. The cuffs were connected to an
oscillometric pressure sensor for measurements of blood
pressure and to a plethysmographic sensor for recordings of
volume pulse form. Ankle–brachial pressure index values were
automatically calculated by dividing the ankle systolic blood
pressures of the right and left sides by the higher brachial
systolic blood pressure of either arm, and the lower value of
ankle–brachial pressure index was used for analysis. baPWV
was calculated automatically according to the following
formula: baPWV=(D1D2)/T, where D1 is the distance
between the suprasternal notch and the ankle obtained by
using the equation D1=0.81299height (in cm)+12.328, D2 is
the distance between the suprasternal notch and the
brachium obtained by using the equation D2=0.21959
height2.0734, and T is the time interval between the wave
front of the brachial waveform and that of the ankle
waveform. The distance between sampling points of baPWV
was calculated automatically by inputting the value of
individual height. The baPWVs measured on the right side
and left side were identical (r=0.95, P<0.001). Therefore,
baPWV values on the left side were used for analysis.19
Hypertension was deﬁned as treatment with oral antihy-
pertensive agents or systolic blood pressure of ≥140 mm Hg
and/or diastolic blood pressure of ≥90 mm Hg without
medication. Diabetes mellitus was deﬁned according to the
American Diabetes Association recommendation.20 Dyslipi-
demia was deﬁned according to the third report of the
National Cholesterol Education Program.21 We deﬁned smok-
ers as those who had ever smoked.
Study Outcomes
The present study had 2 primary outcomes: The ﬁrst primary
outcome was coronary events, including fatal or nonfatal
myocardial infarction, coronary artery restenosis, and de novo
coronary artery stenosis as conﬁrmed by diagnostic imaging (ie,
coronary angiography, cardiac nuclear scintigraphy, or coro-
nary computed tomography), and the second primary outcome
was a composite of coronary events, stroke, heart failure, or
sudden death. Deﬁnitions of the clinical outcomes have been
provided previously.17 All cardiovascular events were reported
to the Efﬁcacy Endpoint Review Committee annually from each
institution. The Committee, consisting of members blinded to
any information with regard to vascular function, assessed the
appropriateness of clinical judgment of cardiovascular events
according to prespeciﬁed criteria. The Committee could
request physicians to provide additional clinical information
on cardiovascular events if needed. Any differences in opinion
under assessment were resolved by discussion, and the
Committee ﬁnally determined whether the cardiovascular
events would be included as outcome events in the analysis.
Sample Size
The rationale for the planned sample size of the subjects has
been described previously.17
Statistical Analysis
Results are presented as meansSD for continuous variables
and as percentages for categorical variables. All reported
probability values were 2-sided, and a probability value of
<0.05 was considered statistically signiﬁcant. Categorical
variables were compared by means of the v2 test. Continuous
variables were compared by using unpaired Student t test.
Receiver-operator characteristic curve analyses were per-
formed to assess the sensitivity and speciﬁcity of measure-
ments of FMD and baPWV for predicting cardiovascular
events. Time-to-event end point analyses were performed by
using the Kaplan–Meier method. We categorized subjects into
2 groups according to the cutoff values of FMD and baPWV.
Cutoff values were determined according to the highest
Youden index from the receiver-operator characteristic curves
for predicting the ﬁrst and second primary outcomes. The log-
rank test was used to compare the groups. We evaluated the
associations of cardiovascular events with FMD and baPWV
after adjustment for age, sex, body mass index, left ventricular
ejection fraction (LVEF), brain natriuretic peptide (BNP), and
cardiovascular risk factors by using Cox proportional hazard
regression analysis. In Model 1, hypertension, dyslipidemia,
diabetes mellitus, and smoking were entered into the model
as cardiovascular risk factors. In Model 2, to adjust potential
confounding factors in which there were signiﬁcant differ-
ences between the groups stratiﬁed according to the cutoff
values of FMD and baPWV, systolic blood pressure and
antihypertensive drug treatment instead of the presence of
hypertension, statin use instead of dyslipidemia, and glucose
level in addition to the presence of diabetes mellitus were
entered into the model as cardiovascular risk factors. We
examined the models with both markers (FMD and baPWV)
and their interaction simultaneously but did not ﬁnd any
signiﬁcant interaction between the biomarkers. We evaluated
the proportional hazards assumption in each model using a
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test based on Schoenfeld residuals (ie, Stata’s estat phtest)
and found no violation. The data were processed using JMP
version 11 (SAS Institute, Cary, NC) and Stata version 15
(Stata Corporation, College Station, TX).
Results
FMD and Clinical Outcomes
A total of 679 patients were registered from May 2010 to
September 2012, and 662 patients (97.4%) completed the
study. Of those patients, 462 were included in the analysis
after excluding patients without any organic coronary artery
stenosis (n=32), those with inadequate FMD recordings
(n=35), those with ankle–brachial pressure index values
<0.9 (n=29), and those without measurement of baPWV, in
whom cardio-ankle vascular index was measured using Vasera
(Fukuda Denshi Co., Ltd., Tokyo, Japan) instead of baPWV for
the assessment of arterial stiffness (n=104) (Figure 1). There
were no signiﬁcant differences in clinical parameters between
patients who were included and those who were excluded
except for high-density lipoprotein cholesterol, glucose, BNP,
and prevalence of prior myocardial infarction (Table S1).
Therefore, 104 excluded patients without baPWV measure-
ment were not systematically different. The baseline clinical
characteristics are summarized in Table 1. Of the 462
subjects, 396 (85.7%) were men and 66 (14.3%) were women,
244 (52.8%) had a history of myocardial infarction, 404
(87.4%) had a history of percutaneous coronary intervention,
454 (98.3%) received antiplatelet drugs, 320 (69.3%) received
angiotensin receptor blockers or angiotensin-converting
enzyme inhibitors, and 394 (85.3%) received statins. The
mean value of systolic blood pressure was 129.016.2
mm Hg, that of low-density lipoprotein cholesterol was
92.827.4 mg/dL, that of LVEF was 60.89.9%, that of
BNP was 35.161.6 pg/mL, that of FMD was 4.82.6%, and
that of baPWV was 1639297 cm/s. During a median follow-
up period of 49.2 months (interquartile range, 43.2–
56.1 months), 10 subjects had myocardial infarction, 15
had coronary artery restenosis, 31 had de novo coronary
artery stenosis, 4 had stroke, 4 had heart failure, and 2 died
suddenly (Table 2). Both of the cutoff values of FMD derived
from receiver-operator characteristic curves for predicting the
ﬁrst and second primary outcomes were 7.1%. Therefore, we
divided subjects into 2 groups according to the cutoff value of
FMD of 7.1%. Clinical characteristics of the subjects on the
basis of FMD are summarized in Table 1. Kaplan–Meier
analysis showed that patients with FMD above the cutoff
value of 7.1% had signiﬁcantly fewer ﬁrst primary outcome
events (coronary events) than those for patients with FMD
below the cutoff value (log-rank P=0.04; Figure 2A). Patients
with FMD above the cutoff value also had signiﬁcantly fewer
second primary outcome events (a composite of coronary
events, stroke, heart failure, or sudden death) than those for
patients with FMD below the cutoff value (log-rank P=0.04;
Figure 2B). Multivariate Cox proportional hazard analyses
revealed that FMD above the cutoff value of 7.1% was a
signiﬁcant predictor of lower risk of the ﬁrst (hazard ratio,
0.27; 95% conﬁdence interval [CI], 0.06–0.74; P=0.008) and
second (hazard ratio, 0.32; 95% CI, 0.09–0.79; P=0.01)
primary outcome events after adjustment of age, sex, body
mass index, hypertension, dyslipidemia, diabetes mellitus,
smoking, LVEF, and BNP (Model 1) (Table 3). FMD above the
cutoff value of 7.1% was also a signiﬁcant predictor of lower
risk of the ﬁrst (hazard ratio, 0.27; 95% CI, 0.07–0.76;
P=0.01) and second (hazard ratio, 0.32; 95% CI, 0.10–0.79;
P=0.01) primary outcome events after adjustment of age, sex,
body mass index, systolic blood pressure, antihypertensive
drug treatment, statin use, glucose, presence of diabetes
mellitus, smoking, LVEF, and BNP (Model 2) (Table 3).
baPWV and Clinical Outcomes
Both of the cutoff values of baPWV derived from receiver-
operator characteristic curves for predicting the ﬁrst and
second primary outcomes were 1731 cm/s. Therefore, we
divided subjects into 2 groups according to the cutoff value of
baPWV of 1731 cm/s. Clinical characteristics of the subjects
and clinical events on the basis of baPWV are summarized in
Tables 4 and 5. Kaplan–Meier analysis showed that patients
with baPWV above the cutoff value of 1731 cm/s had
signiﬁcantly more ﬁrst primary outcome events than those for
patients with baPWV below the cutoff value (log-rank P=0.03;
Figure 3A). Patients with baPWV above the cutoff value also
had signiﬁcantly more second primary outcome events than
those for patients with baPWV below the cutoff value (log-rank
679 patients with CAD enrolled in FMD-J study A
Assessed for eligibility
32 patients without coronary artery stenosis
35 patients with inadequate FMD recordings
29 patients with ABI <0.9
104 patients without baPWV measurement
462 patients were included in the analysis
17 lost to follow-up 
662 patients completed study with follow-up to 3 years
Figure 1. Flow chart of the study design from screening to
completion of the trial. ABI indicates ankle–brachial pressure
index; baPWV, brachial–ankle pulse wave velocity; CAD, coronary
artery disease; FMD, ﬂow-mediated vasodilation; FMD-J, Flow-
Mediated Dilation Japan.
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P=0.001; Figure 3B). Multivariate Cox proportional hazard
analyses revealed that baPWV above the cutoff value of
1731 cm/s was a signiﬁcant predictor of the ﬁrst (hazard
ratio, 1.86; 95% CI, 1.01–3.44; P=0.04) and second (hazard
ratio, 2.19; 95% CI, 1.23–3.90; P=0.008) primary outcome
events in Model 1 (Table 3). baPWV above the cutoff value of
1731 cm/s was also a signiﬁcant predictor of the ﬁrst (hazard
ratio, 1.99; 95% CI, 1.04–3.82; P=0.04) and second (hazard
ratio, 2.17; 95% CI, 1.18–4.00; P=0.01) primary outcome
events in Model 2 (Table 3).
Combination of FMD and baPWV and Clinical
Outcomes
We next divided the 462 subjects into 4 groups according to
the cutoff values of FMD of 7.1% and baPWV of 1731 cm/s.
Table 1. Clinical Characteristics of the Subjects on the Basis of Cutoff Value of FMD
Variables
All Subjects High FMD (>7.1%) Low FMD (≤7.1%)
P Value(n=462) (n=77) (n=385)
Age, y 63.88.7 61.19.9 64.38.3 0.003
Men, n (%) 396 (85.7) 62 (80.5) 334 (86.8) 0.17
Body mass index, kg/m2 24.83.6 24.74.3 24.83.5 0.85
Systolic blood pressure, mm Hg 129.016.2 128.216.2 129.116.2 0.66
Diastolic blood pressure, mm Hg 74.810.6 74.710.9 74.810.5 0.94
Heart rate, bpm 66.512.0 67.613.8 66.311.6 0.37
Total cholesterol, mg/dL 169.931.7 170.228.7 169.832.2 0.92
Triglycerides, mg/dL 138.094.0 145.478.1 136.696.9 0.45
HDL cholesterol, mg/dL 50.413.1 49.411.0 50.613.5 0.44
LDL cholesterol, mg/dL 92.827.4 92.326.0 92.927.7 0.84
Glucose, mg/dL 119.537.2 116.433.8 120.137.9 0.43
HbA1c, % (n=347) 6.41.0 6.20.8 6.51.0 0.02
Creatinine, mg/dL 0.850.24 0.830.17 0.860.25 0.28
eGFR, mL/min per 1.73 m2 71.917.6 72.816.0 71.718.0 0.65
Smoker, n (%) 313 (70.2) 47 (62.7) 266 (71.7) 0.13
Complications, n (%)
Hypertension 433 (93.7) 72 (93.5) 361 (93.8) 0.93
Dyslipidemia 436 (94.4) 74 (96.1) 362 (94.0) 0.45
Diabetes mellitus 178 (38.5) 23 (29.9) 155 (40.3) 0.08
Prior myocardial infarction 244 (52.8) 39 (50.7) 205 (53.3) 0.68
Prior coronary intervention 404 (87.4) 74 (96.1) 330 (85.7) 0.005
Medication use, n (%)
Antiplatelet drugs 454 (98.3) 76 (98.7) 378 (98.2) 0.74
ARBs/ACEIs 320 (69.3) 49 (63.6) 271 (70.4) 0.25
b-Blockers 219 (47.4) 39 (50.7) 180 (46.8) 0.53
Antidiabetic drugs 145 (31.4) 18 (23.4) 127 (33.0) 0.09
Statins 394 (85.3) 68 (88.3) 326 (84.7) 0.40
Left ventricular ejection fraction, % 60.89.9 61.310.5 60.79.8 0.63
BNP, pg/mL 35.161.6 30.839.0 35.965.1 0.53
FMD, % 4.82.6 9.01.5 3.91.8 <0.001
baPWV, cm/s 1639297 1564284 1654297 0.02
All results are presented as meanSD. ACEIs indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; baPWV, brachial–ankle pulse wave velocity; BNP,
brain natriuretic peptide; bpm, beats per minute; eGFR, estimated glomerular ﬁltration rate; FMD, ﬂow-mediated vasodilation; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
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Clinical characteristics of the subjects and clinical events
according to the cutoff values of FMD and baPWV are
summarized in Tables 6 and 7. There were signiﬁcant
differences between Kaplan–Meier curves of cumulative
event-free survival of the ﬁrst primary outcome for the 4
subgroups of patients categorized according to the cutoff
values of FMD and baPWV (log-rank P=0.04; Figure 4A).
Multivariate Cox proportional hazard analysis revealed that a
combination of FMD below the cutoff value and baPWV below
the cutoff value (hazard ratio, 3.79; 95% CI, 1.11–23.73;
P=0.03) and a combination of FMD below the cutoff value and
baPWV above the cutoff value (hazard ratio, 6.84; 95% CI,
1.87–44.31; P=0.002) were signiﬁcant predictors of the ﬁrst
primary outcome events in Model 1 (Table 3). A combination
of FMD below the cutoff value and baPWV below the cutoff
value (hazard ratio, 3.61; 95% CI, 1.06–22.55; P=0.04) and a
combination of FMD below the cutoff value and baPWV above
the cutoff value (hazard ratio, 7.07; 95% CI, 1.89–46.35;
P=0.002) were also signiﬁcant predictors of the ﬁrst primary
outcome events in Model 2 (Table 3). There were also
signiﬁcant differences between Kaplan–Meier curves of
cumulative event-free survival of the second primary outcome
(log-rank P=0.003; Figure 4B). Multivariate Cox proportional
hazard analysis revealed that a combination of FMD below the
cutoff value and baPWV below the cutoff value (hazard ratio,
4.05; 95% CI, 1.20–25.28; P=0.02) and a combination of FMD
below the cutoff value and baPWV above the cutoff value
(hazard ratio, 8.38; 95% CI, 2.34–53.77; P<0.001) were
signiﬁcant predictors of the second primary outcome events
in Model 1 (Table 3). A combination of FMD below the cutoff
value and baPWV below the cutoff value (hazard ratio, 3.87;
95% CI, 1.15–24.09; P=0.03) and a combination of FMD
below the cutoff value and baPWV above the cutoff value
(hazard ratio, 8.02; 95% CI, 2.21–51.79; P<0.001) were also
signiﬁcant predictors of the second primary outcome events
in Model 2 (Table 3).
Table 2. Clinical Outcomes of the Subjects on the Basis of Cutoff Value of FMD
Variables, n (%)
All Subjects High FMD (>7.1%) Low FMD (≤7.1%)
P Value(n=462) (n=77) (n=385)
Acute myocardial infarction 10 (2.2) 0 (0.0) 10 (2.6) 0.05
Coronary artery restenosis 15 (3.2) 1 (1.3) 14 (3.6) 0.24
de novo coronary artery stenosis 31 (6.7) 4 (5.2) 27 (7.0) 0.55
Stroke 4 (0.9) 0 (0.0) 4 (1.0) 0.23
Heart failure 4 (0.9) 0 (0.0) 4 (1.0) 0.23
Sudden death 2 (0.4) 1 (1.3) 1 (0.3) 0.28
FMD indicates ﬂow-mediated vasodilation.
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Figure 2. Kaplan–Meier curves of cumulative event-free survival of the ﬁrst primary outcome (coronary events) (A) and the second primary
outcome (coronary events, stroke, heart failure, or sudden death) (B) in subgroups of subjects categorized according to the cutoff value of ﬂow-
mediated vasodilation (FMD). The P value was calculated from the log-rank test.
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Discussion
In the present study, we demonstrated that FMD and baPWV
were signiﬁcant predictors of cardiovascular events indepen-
dent of conventional cardiovascular risk factors in patients
with established CAD. In addition, we demonstrated that the
combination of FMD and baPWV provided further cardiovas-
cular risk stratiﬁcation of patients with CAD. To our knowl-
edge, this is the ﬁrst prospective multicenter study showing
the usefulness of FMD measurement alone, baPWV measure-
ment alone, and the combination of FMD and baPWV
measurements for predicting cardiovascular events in
patients with CAD. Participants enrolled in the present study
were well-managed stable CAD patients who had high rates of
adherence to guideline-based therapies and who had been
under regular follow-up for at least 6 months. Therefore, our
ﬁndings suggest that measurements of FMD and baPWV
might be useful for risk assessment in well-managed stable
CAD patients receiving guideline-based standard therapies.
For asymptomatic patients without a history of atheroscle-
rotic cardiovascular disease (ASCVD), risk stratiﬁcation tools
have been developed and validated to provide the foundation
for targeted preventive efforts based on the individual’s
predicted risk with the concept of targeting the intensity of
drug treatment interventions to the severity of the patient’s
cardiovascular risk.22–25 On the other hand, patients with
ASCVD have been referred to as high-risk patients for whom
prompt initiation of guideline-recommended therapies should
be considered to reduce the risk. Therefore, risk stratiﬁcation
strategies have not been well established. However, in the
context of the growing number of evidence-based therapies
that reduce cardiac morbidity and mortality in patients with
high risk for cardiovascular events who are receiving standard
therapy, risk stratiﬁcation of high-risk patients, such as those
with CAD, may be helpful to select candidates for individu-
alized intensive therapies who could gain the greatest beneﬁt
from the emerging therapies.
Measurement of FMD of the brachial artery has been used
as a method for assessment of endothelial function in
humans.26,27 In addition, several lines of evidence have
demonstrated that FMD could be used not only as an index of
endothelial function but also as a prognostic marker of
cardiovascular events.11,28 Recent meta-analyses have shown
that FMD is a signiﬁcant predictor of cardiovascular events
independent of conventional cardiovascular risk factors.12–14
Table 3. Association of Primary End Points With FMD, baPWV, and FMD Combined With baPWV During Follow-Up
Variables
Hazard Ratio (95% Conﬁdence Interval); P Value
First Primary Outcome Second Primary Outcome
Unadjusted Model 1* Model 2† Unadjusted Model 1* Model 2†
FMD (%)
FMD ≤7.1% 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
FMD >7.1% 0.36 (0.11–0.89);
0.02
0.27 (0.06–0.74);
0.008
0.27 (0.07–0.76);
0.01
0.39 (0.14–0.88);
0.02
0.32 (0.09–0.79);
0.01
0.32 (0.10–0.79);
0.01
baPWV, cm/s
baPWV <1731 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
baPWV ≥1731 1.79 (1.05–3.03);
0.03
1.86 (1.01–3.44);
0.04
1.99 (1.04–3.82);
0.04
2.20 (1.35–3.59);
0.002
2.19 (1.23–3.90);
0.008
2.17 (1.18–4.00);
0.01
FMD+baPWV
Group 1 (FMD >7.1%,
baPWV <1731 cm/s)
1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 (FMD >7.1%,
baPWV ≥1731 cm/s)
3.64 (0.44–30.35);
0.21
1.99 (0.09–21.47);
0.59
1.98 (0.09–21.65);
0.60
5.41 (0.90–41.09);
0.06
3.83 (0.45–32.81);
0.20
3.44 (0.40–29.84);
0.24
Group 3 (FMD ≤7.1%,
baPWV <1731 cm/s)
3.59 (1.08–22.21);
0.03
3.79 (1.11–23.73);
0.03
3.61 (1.06–22.55);
0.04
3.83 (1.16–23.67);
0.02
4.05 (1.20–25.28);
0.02
3.87 (1.15–24.09);
0.03
Group 4 (FMD ≤7.1%,
baPWV ≥1731 cm/s)
5.78 (1.17–35.99);
0.003
6.84 (1.87–44.31);
0.002
7.07 (1.89–46.35);
0.002
7.46 (2.25–46.15);
<0.001
8.38 (2.34–53.77);
<0.001
8.02 (2.21–51.79);
<0.001
First primary end point is coronary events, including fatal or nonfatal myocardial infarction, coronary artery restenosis, or de novo coronary artery stenosis as conﬁrmed by diagnostic
imaging. Second primary end point is a composite of coronary events, death from cardiovascular causes, stroke, heart failure, and sudden death. baPWV indicates brachial–ankle pulse
wave velocity; FMD, ﬂow-mediated vasodilation.
*Model 1: adjusted for age, sex, body mass index, the presence of hypertension, dyslipidemia, and diabetes mellitus, smoking, left ventricular ejection fraction, and brain natriuretic
peptide.
†Model 2: adjusted for age, sex, body mass index, systolic blood pressure, antihypertensive drug treatment, statin use, glucose, the presence of diabetes mellitus, smoking, left ventricular
ejection fraction, and brain natriuretic peptide.
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However, there have been very few studies in which the
predictive value of FMD in patients with established CAD was
investigated.29,30 In addition, the predictive value of FMD in
patients with high risk for cardiovascular events is controver-
sial. Witte et al31 reported that FMD was signiﬁcantly related
to the principal cardiovascular risk factors and estimated 10-
year risk of CAD in low-risk populations but not in medium-
and high-risk populations categorized according to the
Framingham risk score, suggesting that measurement of
FMD is not useful for risk assessment in individuals at high
risk for cardiovascular events, such as those with a history of
CAD. However, Gokce et al32 showed that patients who had
peripheral artery disease undergoing vascular surgery and
who were in the upper tertile of FMD (>8.1%) had signiﬁcantly
fewer cardiovascular events than those in patients in the
lowest and middle tertiles of FMD with no difference in event-
Table 4. Clinical Characteristics of the Subjects on the Basis of Cutoff Value of baPWV
Variables
Low baPWV (<1731 cm/s) High baPWV (≥1731 cm/s)
P Value(n=312) (n=150)
Age, y 61.69.1 68.25.7 <0.001
Men, n (%) 271 (86.9) 125 (83.3) 0.32
Body mass index, kg/m2 25.23.9 23.92.7 <0.001
Systolic blood pressure, mm Hg 125.915.4 135.416.0 <0.001
Diastolic blood pressure, mm Hg 74.610.6 75.210.6 0.60
Heart rate, bpm 66.012.2 67.611.5 0.19
Total cholesterol, mg/dL 169.430.8 171.033.6 0.61
Triglycerides, mg/dL 138.899.5 136.581.7 0.81
HDL cholesterol, mg/dL 50.312.9 50.813.6 0.68
LDL cholesterol, mg/dL 92.426.0 93.730.1 0.65
Glucose, mg/dL 116.036.2 126.838.3 0.003
HbA1c, % (n=347) 6.30.9 6.71.0 0.004
Creatinine, mg/dL 0.840.23 0.880.26 0.06
eGFR, mL/min per 1.73 m2 73.717.0 68.118.3 0.001
Smoker, n (%) 217 (71.9) 96 (66.7) 0.27
Complications, n (%)
Hypertension 290 (93.0) 143 (95.3) 0.31
Dyslipidemia 300 (96.2) 136 (90.7) 0.02
Diabetes mellitus 109 (34.9) 69 (46.0) 0.02
Prior myocardial infarction 170 (54.5) 74 (49.3) 0.30
Prior coronary intervention 278 (89.1) 126 (84.0) 0.13
Medication use, n (%)
Antiplatelet drugs 307 (98.4) 147 (98.0) 0.76
ARBs/ACEIs 213 (68.3) 107 (71.3) 0.50
b-Blockers 157 (50.3) 62 (41.3) 0.07
Antidiabetic drugs 87 (27.9) 58 (38.7) 0.02
Statins 281 (90.1) 113 (75.3) <0.001
Left ventricular ejection fraction, % 60.610.2 61.49.3 0.44
BNP, pg/mL 28.633.7 49.497.0 0.001
FMD, % 5.02.6 4.32.4 0.01
baPWV, cm/s 1474157 1981215 <0.001
All results are presented as meanSD. ACEI indicates angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; baPWV, brachial–ankle pulse wave velocity; BNP,
brain natriuretic peptide; bpm, beats per minute; eGFR, estimated glomerular ﬁltration rate; FMD, ﬂow-mediated vasodilation; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
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free survival rates between the lowest and middle tertiles,
suggesting that FMD could be used for identifying individuals
at low risk for cardiovascular events among patients generally
considered to be at high cardiovascular risk. In the present
study, CAD patients with FMD >7.1% had signiﬁcantly fewer
cardiovascular events than those in CAD patients with FMD
≤7.1%. In addition, FMD >7.1% was a signiﬁcant predictor of
lower risk of cardiovascular events independent of conven-
tional cardiovascular risk factors, LVEF, and BNP (hazard ratio,
0.27; 95% CI, 0.06–0.74; P=0.008 for the ﬁrst primary
outcomes in Model 1; hazard ratio, 0.32; 95% CI, 0.09–0.79;
P=0.01 for the second primary outcomes in Model 1; hazard
ratio, 0.27; 95% CI, 0.07–0.76; P=0.01 for the ﬁrst primary
outcomes in Model 2; hazard ratio, 0.32; 95% CI, 0.10–0.79;
P=0.01 for the second primary outcomes in Model 2).
According to a previous study conducted in 4533 subjects
from the FMD-J study cohort, reference values of FMD were
6.5% in men and 7.4% in women.18 Taken together, these
ﬁndings suggest that measurement of FMD in patients with
CAD might be clinically useful for identifying individuals with
normally maintained endothelial function who are at low risk
for recurrent cardiovascular events.
We have no information on the reproducibility of FMD
measurements within each participant institution. However,
the correlation coefﬁcients between FMD analyzed at the core
laboratory and institutions with a small number of enrolled
study subjects were not satisfactory (R<0.60), raising the
possibility that the reproducibility of FMD measurements
performed at a less experienced institution was low, which
could provide misleading information for risk stratiﬁcation of
patients with CAD.18 Although the concept of the endothelial
function test seems simple, FMD measurement is technically
challenging. Therefore, it is recommended that FMD mea-
surement be performed by a skilled and trained operator with
a comprehensive understanding of the principle of FMD.
Recently, baPWV has been used for assessment of arterial
stiffness in humans. It has been shown that baPWV correlates
closely with directly measured aortic PWV and carotid–
femoral PWV used as the criterion standard for noninvasive
assessment of central arterial stiffness.33,34 Compared with
the measurement of carotid–femoral PWV requiring a skilled
technique and exposure of the inguinal region during
measurement, baPWV measurement is a simple method using
a separate oscillometric cuff for each of the 4 extremities.
Several lines of evidence have demonstrated that baPWV
could be used not only as an index of atrial stiffness but
also as a prognostic marker of cardiovascular events.35
However, there have been few studies in which the predictive
Table 5. Clinical Outcomes of the Subjects on the Basis of
Cutoff Value of baPWV
Variables, n (%)
Low baPWV
(<1731 cm/s)
High baPWV
(≥1731 cm/s)
P Value(n=312) (n=150)
Acute myocardial infarction 8 (2.6) 2 (1.3) 0.37
Coronary artery restenosis 7 (2.2) 8 (5.3) 0.09
de novo coronary
artery stenosis
14 (4.5) 17 (11.3) 0.008
Stroke 1 (0.3) 3 (2.0) 0.08
Heart failure 0 (0.0) 4 (2.7) 0.003
Sudden death 1 (0.3) 1 (0.7) 0.61
baPWV indicates brachial–ankle pulse wave velocity.
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Figure 3. Kaplan–Meier curves of cumulative event-free survival of the ﬁrst primary outcome (coronary events) (A) and the second primary
outcome (coronary events, stroke, heart failure, or sudden death) (B) in subgroups of subjects categorized according to the cutoff value of
brachial–ankle pulse wave velocity (baPWV). The P value was calculated from the log-rank test.
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value of baPWV in patients with established CAD was
investigated.30,36 In the present study, CAD patients with
baPWV ≥1731 cm/s had signiﬁcantly more cardiovascular
events than those in patients with baPWV <1731 cm/s. In
addition, baPWV ≥1731 cm/s was a signiﬁcant predictor of
increased risk of cardiovascular events independent of
conventional cardiovascular risk factors, LVEF, and BNP
(hazard ratio, 1.86; 95% CI, 1.01–3.44; P=0.004 for the ﬁrst
primary outcomes in Model 1; hazard ratio, 2.19; 95% CI,
1.23–3.90; P=0.008 for the second primary outcomes in
Model 1; hazard ratio, 1.99; 95% CI, 1.04–3.82; P=0.04 for
the ﬁrst primary outcomes in Model 2; hazard ratio, 2.17; 95%
Table 6. Clinical Characteristics of the Subjects on the Basis of Cutoff Values of FMD and baPWV
Variables
Group 1 Group 2 Group 3 Group 4
P Value
FMD >7.1% FMD ≤7.1%
baPWV <1731 cm/s baPWV ≥1731 cm/s baPWV <1731 cm/s baPWV ≥1731 cm/s
(n=60) (n=17) (n=252) (n=133)
Age, y 59.210.0 67.86.1 62.28.7 68.35.7 <0.001
Men, n (%) 48 (80.0) 14 (82.4) 223 (88.5) 111 (83.5) 0.28
Body mass index, kg/m2 25.14.6 23.42.5 25.23.7 24.02.8 0.003
Systolic blood pressure, mm Hg 126.516.7 134.212.9 125.715.1 135.516.4 <0.001
Diastolic blood pressure, mm Hg 74.610.1 75.013.9 74.610.7 75.210.2 0.96
Heart rate, bpm 67.814.2 66.912.5 65.511.7 67.611.5 0.32
Total cholesterol, mg/dL 169.628.1 172.631.7 169.331.4 170.834.0 0.96
Triglycerides, mg/dL 149.384.9 131.746.8 136.2102.6 137.185.3 0.79
HDL cholesterol, mg/dL 49.211.4 50.29.7 50.513.2 50.914.0 0.87
LDL cholesterol, mg/dL 91.126.1 96.126.1 92.726.1 93.430.6 0.91
Glucose, mg/dL 111.829.6 133.042.8 117.037.6 126.037.8 0.02
HbA1c, % (n=347) 6.00.6 6.71.2 6.41.0 6.61.0 0.003
Creatinine, mg/dL 0.820.16 0.840.18 0.840.24 0.890.27 0.21
eGFR, mL/min per 1.73 m2 73.515.4 70.218.2 73.817.4 67.918.4 0.01
Smoker, n (%) 36 (61.0) 11 (68.8) 181 (74.5) 85 (66.4) 0.15
Complications, n (%)
Hypertension 56 (93.3) 16 (94.1) 234 (92.9) 127 (95.5) 0.78
Dyslipidemia 59 (98.3) 15 (88.2) 241 (95.6) 121 (91.0) 0.08
Diabetes mellitus 15 (25.0) 8 (47.1) 94 (37.3) 61 (45.9) 0.04
Prior myocardial infarction 32 (53.3) 7 (41.2) 138 (54.8) 67 (50.4) 0.65
Prior coronary intervention 58 (96.7) 16 (94.1) 220 (87.3) 110 (82.7) 0.02
Medication use, n (%)
Antiplatelet drugs 59 (98.3) 17 (100.0) 248 (98.4) 130 (97.7) 0.84
ARBs/ACEIs 38 (63.3) 11 (64.7) 175 (69.4) 96 (72.2) 0.64
b-Blockers 32 (53.3) 7 (41.2) 125 (49.6) 55 (41.4) 0.31
Antidiabetic drugs 11 (18.3) 7 (41.2) 76 (30.2) 51 (38.4) 0.03
Statins 54 (90.0) 14 (82.4) 227 (90.1) 99 (74.4) <0.001
Left ventricular ejection fraction, % 61.010.9 62.79.1 60.510.0 61.29.3 0.79
BNP, pg/mL 27.838.2 40.941.2 28.832.7 50.5102.2 0.01
FMD, % 9.01.5 9.01.7 4.01.9 3.71.8 <0.001
baPWV, cm/s 1447149 1978260 1481159 1981210 <0.001
All results are presented as meanSD. ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; baPWV, brachial–ankle pulse wave velocity; BNP,
brain natriuretic peptide; bpm, beats per minute; eGFR, estimated glomerular ﬁltration rate; FMD, ﬂow-mediated vasodilation; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
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CI, 1.18–4.00; P=0.01 for the second primary outcomes in
Model 2), being consistent with the results of a previous study
showing that baPWV ≥1730 cm/s was independently asso-
ciated with increased risk of cardiovascular events in patients
with type 2 diabetes mellitus with CAD.36 These ﬁndings
suggest that measurement of baPWV in patients with CAD
might be clinically useful for identifying individuals who have
increased arterial stiffness and who are at high risk for
recurrent cardiovascular events. A literature-based meta-
analysis, in which more than half of the study participants
were very high-risk patients, such as those with end-stage
renal disease or ASCVD, and a recent individual participant
data meta-analysis investigating the association of baPWV
with the risk of development of ASCVD in subjects without a
history of ASCVD, have demonstrated that elevated baPWV is
associated with increased risk of cardiovascular events
independent of conventional risk factors.15,16 Taken together,
the ﬁndings of our study support the broad applicability of
baPWV for risk stratiﬁcation in general clinical settings
regardless of cardiovascular risk.
We also investigated the predictive value of the combina-
tion of FMD and baPWV for cardiovascular events. Although a
previous single-center study showed the predictive value of
the combination of FMD and baPWV in patients with chronic
CAD, the optimal cutoff values of FMD and baPWV for
predicting cardiovascular events were not assessed.30 In the
present study, there were signiﬁcant differences between the
Kaplan–Meier curves for the ﬁrst and second primary
outcome events among the 4 groups categorized according
to the cutoff values of FMD and baPWV. In addition,
Table 7. Clinical Outcome of the Subjects on the Basis of Cutoff Values of FMD and baPWV
Variables
Group 1 Group 2 Group 3 Group 4
P Value
FMD >7.1% FMD ≤7.1%
baPWV <1731 cm/s baPWV ≥1731 cm/s baPWV <1731 cm/s baPWV ≥1731 cm/s
(n=60) (n=17) (n=252) (n=133)
Acute myocardial infarction 0 (0.0) 0 (0.0) 8 (3.2) 2 (1.5) 0.19
Coronary artery restenosis 0 (0.0) 1 (5.9) 7 (2.8) 7 (5.3) 0.11
de novo coronary artery stenosis 2 (3.3) 2 (11.8) 12 (4.8) 15 (11.3) 0.06
Stroke 0 (0.0) 0 (0.0) 1 (0.4) 3 (2.3) 0.24
Heart failure 0 (0.0) 0 (0.0) 0 (0.0) 4 (3.0) 0.02
Sudden death 0 (0.0) 1 (5.9) 1 (0.4) 0 (0.0) 0.16
baPWV indicates brachial–ankle pulse wave velocity; FMD, ﬂow-mediated vasodilation.
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Figure 4. Kaplan–Meier curves of cumulative event-free survival of the ﬁrst primary outcome (coronary events) (A) and the second primary
outcome (coronary events, stroke, heart failure, or sudden death) (B) in subgroups of subjects categorized as being above or below the cutoff
values of ﬂow-mediated vasodilation (FMD) and brachial–ankle pulse wave velocity (baPWV). The P value was calculated from the log-rank test.
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multivariate regression analysis showed a stepwise increase
in the calculated risk ratio for the ﬁrst primary outcome
events (hazard ratio, 3.79; 95% CI, 1.11–23.73; P=0.03 for
Group 3 in Model 1; hazard ratio, 6.84; 95% CI, 1.87–44.31;
P=0.002 for Group 4 in Model 1; hazard ratio, 3.61; 95% CI,
1.06–22.55; P=0.04 for Group 3 in Model 2; hazard ratio,
7.07; 95% CI, 1.89–46.35; P=0.002 for Group 4 in Model 2)
and the second primary outcome events (hazard ratio, 4.05;
95% CI, 1.20–25.28; P=0.02 for Group 3 in Model 1; hazard
ratio, 8.38; 95% CI, 2.34–53.77; P<0.001 for Group 4 in
Model 1; hazard ratio, 3.87; 95% CI, 1.15–24.09; P=0.03 for
Group 3 in Model 2; hazard ratio, 8.02; 95% CI, 2.21–51.79;
P<0.001 for Group 4 in Model 2). These ﬁndings suggest that
the combination of FMD and baPWV provides further risk
stratiﬁcation of patients with CAD for recurrent cardiovascular
events than does FMD alone or baPWV alone. Therefore,
recommended procedures for risk assessment in patients
with CAD could be as follows. First, FMD is measured to
identify individuals with normally maintained endothelial
function (FMD >7.1%) who are considered to be at low risk
for recurrent cardiovascular events. Second, in patients with
impaired endothelial function (FMD ≤7.1%), measurement of
baPWV is recommended to identify individuals with increased
arterial stiffness (baPWV ≥1731 cm/s) who are at especially
high risk for recurrent cardiovascular events.
There are some limitations in this study. First, there is a
wide range of variations in the protocols for measurement
of FMD because of differences in testing modality, position
of cuff placement, cuff inﬂation pressure for artery occlu-
sion, cuff inﬂation time, and timing of measurement of peak
artery diameter, resulting in a difference in diagnostic
criteria among clinical studies. Therefore, the cutoff value of
FMD obtained in this study is applicable only to Japanese
CAD patients in whom FMD was measured in accordance
with the same protocol as that used in this study. Second,
there were signiﬁcant differences in hemoglobin A1c
(HbA1c) levels between the groups stratiﬁed according to
the cutoff values of FMD and baPWV, which may be a
potential confounding factor associated with changes in
FMD and baPWV. Although HbA1c levels should be entered
into the multivariate model, information on HbA1c levels
was available in only 347 of the 462 participants, leading to
a low level of statistical power with a decreased number of
subjects in the multivariate analysis. Therefore, we did not
enter HbA1c levels into the multivariate analyses and could
not, therefore, exclude the possibility of a confounding
effect of HbA1c levels on vascular function in multivariate
analyses. Third, a previous study showed that CAD patients
with improved FMD after 6 months of optimized therapy
(responders) had signiﬁcantly fewer cardiovascular events
than those for patients with persistently impaired FMD
despite the optimized therapy (nonresponders) during
36 months of follow-up.37 In the present study, angioten-
sin-converting enzyme inhibitors or angiotensin receptor
blockers and statins, which are known to improve vascular
function, were all highly utilized. In addition, CAD patients
who had been under regular follow-up for at least 6 months
were enrolled in this study. Although we have no informa-
tion on FMD and baPWV before the initiation of evidence-
based therapies, we cannot deny the possibility that the
difference in the response of vascular function to evidence-
based therapies predisposed to cardiovascular events with
elevated risk in the nonresponders.
In conclusion, in CAD patients with high adherence to
guideline-based therapies, measurements of FMD and baPWV
improved cardiovascular risk assessment. Both FMD and
baPWV were signiﬁcant predictors of recurrent cardiovascular
events independent of conventional risk factors. In addition,
the combination of FMD and baPWV provided further risk
stratiﬁcation of patients with CAD. FMD of 7.1% and baPWV of
1731 cm/s may be considered as reference values for
recurrent cardiovascular events in patients with CAD. Mea-
surements of both FMD and baPWV are recommended for risk
assessment in patients with CAD. Further studies are needed
for the justiﬁcation for and validation of the cutoff values of
FMD and baPWV to differentiate high- and low-risk groups for
clinical implementation and to determine whether the cutoff
values of FMD and baPWV are universally valid, whether
individualized intensive therapies for patients with CADwho are
judged to be at especially high risk for recurrent cardiovascular
events by measurements of FMD and baPWV improve cardio-
vascular outcomes, and whether those vascular function tests
eventually contribute to lower management costs.
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Supplemental Material 
Table S1. Clinical Characteristics of the Included Subjects and Excluded Subjects without 
baPWV Measurement. 
All results are presented as mean±SD. 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular 
filtration rate; ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme 
inhibitor; BNP, brain natriuretic peptide; FMD, flow-mediated vasodilation; baPWV, brachial 
ankle pulse wave velocity. 
Included Excluded 
Variables (n=462) (n=104) P value 
Age, yr 63.8±8.7 63.3±8.0 0.63 
Men, n (%) 396 (85.7) 85 (81.7) 0.31 
Body mass index, kg/m2 24.8±3.6 25.2±3.8 0.34 
Systolic blood pressure, mm Hg 129.0±16.2 125.9±15.6 0.08 
Diastolic blood pressure, mm Hg 74.8±10.6 72.6±10.6 0.06 
Heart rate, bpm 66.5±12.0 66.6±11.6 0.95 
Total cholesterol, mg/dL 169.9±31.7 163.7±27.8 0.07 
Triglycerides, mg/dL 138.0±94.0 133.1±62.1 0.61 
HDL cholesterol, mg/dL  50.4±13.1 47.6±12.9 0.04 
LDL cholesterol, mg/dL 92.8±27.4 89.5±25.3 0.26 
Glucose, mg/dL 119.5±37.2 108.6±27.7 0.005 
HbA1c, % (n=347) 6.4±1.0 6.4±1.0 0.96 
Creatinine, mg/dL 0.85±0.24 0.88±0.25 0.37 
eGFR, ml/min/1.73 m2 71.9±17.6 68.9±15.4 0.11 
Smoker, n (%) 313 (70.2) 78 (76.5) 0.20 
Complications, n (%) 
Hypertension 433 (93.7) 100 (96.2) 0.32 
Dyslipidemia 436 (94.4) 98 (94.2) 0.96 
Diabetes mellitus 178 (38.5) 36 (34.6) 0.46 
Prior myocardial infarction 244 (52.8) 43 (41.4) 0.03 
Prior coronary intervention 404 (87.4) 97 (93.3) 0.07 
Medication use, n (%) 
Antiplatelet drugs 454 (98.3) 100 (96.2) 0.21 
ARBs/ACEIs 320 (69.3) 69 (66.4) 0.56 
β-blockers 219 (47.4) 47 (45.2) 0.68 
Antidiabetic drugs 145 (31.4) 31 (29.8) 0.75 
Statins 394 (85.3) 89 (85.6) 0.94 
Left ventricular ejection fraction, % 60.8±9.9 60.6±11.4 0.83 
BNP, pg/mL  35.1±61.6 57.0±112.3 0.007 
FMD, % 4.8±2.6 4.9±2.9 0.53 
